公开(公告)号：US20130203167A1

公开(公告)日：2013-08-08

申请号：US13415474

申请日：2012-03-08

Applicant: Michael S. Cosgrove ,  Anamika Patel

Inventor： Michael S. Cosgrove ,  Anamika Patel

IPC: C12N9/99

CPC classification number: C12N9/99 ,  C07K14/4702 ,  C12Y201/01043

Abstract: Disclosed in this specification is a method for inhibiting the formation of vertebrate SET1 family core complexes. A guanidinium-containing molecule is used to competitively inhibit the binding of the N-SET region of a SET1 protein to WDR5, thus inhibiting the formation of the SET1 family core complex. The guanidinium-containing molecule may be, for example, an arginine-containing peptide.

Abstract translation: 在本说明书中公开的是抑制脊椎动物SET1家族核心复合物形成的方法。 使用含胍基分子竞争性地抑制SET1蛋白的N-SET区与WDR5的结合，从而抑制SET1家族核心复合物的形成。 含有胍基的分子可以是例如含精氨酸的肽。

公开(公告)号：US07968281B2

公开(公告)日：2011-06-28

申请号：US11912860

申请日：2006-06-23

Applicant: Yusuke Nakamura ,  Yoichi Furukawa ,  Ryuji Hamamoto ,  Shuichi Nakatsuru

Inventor： Yusuke Nakamura ,  Yoichi Furukawa ,  Ryuji Hamamoto ,  Shuichi Nakatsuru

IPC: C12Q1/00 ,  G01N33/53

CPC classification number: G01N33/5011 ,  C12Q1/48 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N2333/4736 ,  G01N2333/91011 ,  G01N2500/02

Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.

Abstract translation: 本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。 本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。 SMYD3（别名ZNFN3A1）的N-末端截短形式具有较高的甲基化活性。 Lys 824是SMYD3的RB1蛋白上优选的甲基化位点。

公开(公告)号：US20090298105A1

公开(公告)日：2009-12-03

申请号：US12497211

申请日：2009-07-02

Applicant: Yi Zhang ,  Ru Cao

Inventor： Yi Zhang ,  Ru Cao

IPC: C12Q1/48 ,  C12N9/10 ,  C12N15/85 ,  C12N5/10

CPC classification number: C12N9/1007 ,  C07K14/82 ,  C07K2319/20 ,  C12N2799/026 ,  C12Y201/01043 ,  G01N2333/91011

Abstract: The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.

Abstract translation: 本发明提供了包含EED，EZH2和SUZ12的复原复合物，其中重构的复合物对组蛋白H3（H3-K27）的赖氨酸27具有组蛋白甲基转移酶（HMTase）活性。 重构的复合物还可以包括RbAp48，AEBP2或两者。 还公开了生产重建复合物的方法，鉴定抑制重构复合物的HTMase活性的化合物的方法和鉴定用于治疗癌症的候选化合物的方法。 还提供了试剂和试剂盒，包括重构的复合物。

公开(公告)号：US20240255509A1

公开(公告)日：2024-08-01

申请号：US18506086

申请日：2023-11-09

Applicant: Aelan Cell Technologies, Inc.

Inventor： Victoria LUNYAK ,  James Robert TOLLERVEY

IPC: G01N33/573 ,  C07K14/47 ,  C07K16/18 ,  C12N9/10 ,  C12P21/02 ,  C12P21/06 ,  G01N33/543 ,  G01N33/68

CPC classification number: G01N33/573 ,  C07K14/47 ,  C07K16/18 ,  C12N9/1007 ,  C12P21/02 ,  C12P21/06 ,  C12Y201/01043 ,  G01N33/54306 ,  G01N33/6896 ,  C12Y201/01 ,  G01N2800/2821 ,  G01N2800/50

Abstract: Provided herein are H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides and methods of use for diagnostics and therapeutics. These H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides may be used in the treatment of methylated H1.0-related diseases or conditions in an individual. These H1.0K180me2 antibodies, H1.0K180me2 proteins, and H1.0K180me2 peptides may also be used for the detection and quantification of a histone H1.0 protein or fragment thereof, comprising a dimethylated lysine at lysine residue 180 (H1.0K180me2); such compositions and methods are useful for detecting replicative senescence, DNA damage, genotoxic stress, radiation exposure, Alzheimer's disease, are useful for monitoring therapeutic regimens, patient stratification, drug screening, and may serve as a marker of biological aging in a system.

公开(公告)号：US11819554B2

公开(公告)日：2023-11-21

申请号：US15760765

申请日：2016-09-16

Applicant: University of Massachusetts

Inventor： Michael R. Green ,  Minggang Fang ,  Walter Kowtoniuk

IPC: A61K31/711 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/395 ,  A61K48/00 ,  A61K31/5377 ,  A61K31/549 ,  A61K31/706 ,  A61K31/713 ,  C12Q1/6883 ,  C12N15/113 ,  A61K31/7088 ,  A61K31/404 ,  A61K31/546 ,  A61K31/167 ,  A61K31/497 ,  A61K31/506 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/522 ,  A61K31/496 ,  A61P25/14 ,  A61P15/02 ,  A61K31/7105

CPC classification number: A61K48/005 ,  A61K31/167 ,  A61K31/404 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/546 ,  A61K31/549 ,  A61K31/706 ,  A61K31/7088 ,  A61K31/711 ,  A61K31/713 ,  A61K31/7105 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/3955 ,  A61K48/0016 ,  A61P15/02 ,  A61P25/14 ,  C12N15/113 ,  C12Q1/6883 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y603/02019

Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).

公开(公告)号：US20190233805A1

公开(公告)日：2019-08-01

申请号：US16151895

申请日：2018-10-04

Applicant: The Regents of the University of California

Inventor： David J Segal ,  Henriette O'Geen ,  Joel P. Mackay ,  Peggy J. Farnham

IPC: C12N9/22 ,  C12N9/10 ,  C07K14/47

CPC classification number: C12N9/22 ,  C07K14/4702 ,  C07K2319/09 ,  C07K2319/43 ,  C07K2319/81 ,  C12N9/1007 ,  C12Y201/01037 ,  C12Y201/01043

Abstract: Provided herein are fusion proteins comprising a catalytically inactive Cas9 domain and an effector domain. The fusion proteins of the present invention can be used to, for example, produce epigenetic modifications at target chromatin sites. Nucleic acids and expression vectors encoding the fusion proteins, as well as cells comprising the fusion proteins, are also provided herein.

公开(公告)号：US20190192533A1

公开(公告)日：2019-06-27

申请号：US16195777

申请日：2018-11-19

Applicant: Duke University

Inventor： Victor J. Dzau ,  Maria Mirotsou

IPC: A61K31/551 ,  A61P9/00 ,  C07D487/04 ,  C07D401/14 ,  A61K45/06 ,  A61K31/437 ,  A61P9/12 ,  A61K35/34 ,  A61P9/10 ,  C12N15/113

CPC classification number: A61K31/551 ,  A61K31/437 ,  A61K35/34 ,  A61K45/06 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  C07D401/14 ,  C07D487/04 ,  C12N15/1137 ,  C12N2310/141 ,  C12N2320/30 ,  C12Y201/01043 ,  C12Y201/01125 ,  C12Y207/10002 ,  C12Y207/11001

Abstract: A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression.

公开(公告)号：US20180363008A1

公开(公告)日：2018-12-20

申请号：US16017157

申请日：2018-06-25

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Yi Zhang ,  Shogo Matoba

IPC: C12N15/877 ,  A01K67/027 ,  C12N15/113 ,  C12N5/0735 ,  C12N5/073

CPC classification number: C12N15/877 ,  A01K67/0273 ,  A01K2227/105 ,  C12N5/0604 ,  C12N5/0606 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2517/04 ,  C12Y201/01043

Abstract: The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT) and the consequent production of nuclear transfer ESC (ntESC) and transgenic cells and/or non-human animals. More specifically, the present invention relates to the discovery that trimethylation of Histone H3-Lysine 9 (H3K9me3) in reprogramming resistant regions (RRRs) in the nuclear genetic material of donor somatic cells prevents efficient somatic cell nuclear reprogramming or SCNT. The present invention provide methods and compositions to decrease H3K9me3 in methods to improve efficacy of SCNT by exogenous or overexpression of the demethylase Kdm4 family and/or inhibiting methylation of H3K9me3 by inhibiting the histone methyltransferases Suv39h1 and/or Suv39h2.

公开(公告)号：US09889180B2

公开(公告)日：2018-02-13

申请号：US14443602

申请日：2013-11-19

Applicant: Agency for Science, Technology and Research

Inventor： Qiang Yu ,  Zhen Ning Wee

IPC: A61K31/713 ,  A61K31/706 ,  A61K31/437 ,  A61K38/21 ,  G01N33/574 ,  C07K16/40 ,  C07K14/57 ,  C12Q1/68 ,  C12N15/113

CPC classification number: A61K38/217 ,  A61K31/437 ,  A61K31/706 ,  A61K31/713 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Y201/01043 ,  G01N33/57492 ,  G01N33/57496 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.

公开(公告)号：US09856479B2

公开(公告)日：2018-01-02

申请号：US15171860

申请日：2016-06-02

Applicant: The General Hospital Corporation

Inventor： Jeannie T. Lee ,  Jing Zhao ,  Kavitha Sarma ,  Mark Borowsky ,  Toshiro Kendrick Ohsumi

IPC: C12N15/11 ,  C12N15/113 ,  C12Q1/68 ,  A61K9/127 ,  A61K31/713

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.